VRVyacheslav Vital'EVich Romanov

Vyacheslav Vital'EVich Romanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vyacheslav Vital'EVich Romanov has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of empagliflozin on biomarkers of renal injury, fibrosis and low-grade inflammation in patients with type 2 diabetes

    by A. I. Korbut, V. V. Romanov, V. V. Klimontov

    BACKGROUND : Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been implemented into the treatment standards for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D). Identification of predictors of the protective effect of SGLT2 inhibitors on the kidneys remains an urgent task. AIM : To evaluate the effects of the SGLT2 inhibitor empagliflozin on the levels of biomarkers of renal injury, fibrosis and low-grade inflammation in patients with T2D with CKD and/or high cardiovascular risk. MATERIALS AND METHODS : This prospective cohort single-center study included 30 patients with T2D newly initiated treatment with an SGLT2 inhibitor. Before and on day 90 of treatment with empagliflozin (10 mg/day), urinary excretion of nephrin, retinol-binding protein 4 (RBP-4), type IV collagen, and fibrosis marker WFDC-2, as well as serum concentrations of high-sensitivity C-reactive protein (hsCRP) and tumor necrosis factor receptor 1A alpha (TNFRSF1A) were determined by ELISA. Twenty healthy individuals were included in the control group. RESULTS : Patients with T2D compared to controls initially demonstrated higher excretion of nephrin (p=0.03), RBP-4 (p=0.001), type IV collagen (p=0.04) and WDFC-2 (p=0.02), as well as higher serum concentrations of hsCRP and TNFSF1A (p=0.03). Empagliflozin treatment was associated with a significant decrease in the excretion of RBP-4 (p=0.04) and TNFRSF1A levels (p0.05). Baseline RBP-4 excretion and serum TNFRSF1A levels were associated with changes in creatinine levels during empagliflozin treatment. CONCLUSION : In patients with T2D with CKD and/or high cardiovascular risk, empagliflozin treatment resulted in decreased urinary excretion of RBP-4 and serum TNFRSF1A levels. These data may indicate a protective effect of empagliflozin on tubular dysfunction and low-grade inflammation.


  • Open Access

    Overweight and obesity in patients with type 1 diabetes: associations with vascular complications and biomarkers of vascular remodeling

    by V. V. Klimontov, A. Yu. Yushin, Yu. F. Semenova, A. I. Korbut, V. V. Romanov, А. Ю. Юшин

    BACKGROUND: The prevalence of overweight and obesity in patients with type 1 diabetes (T1D) is increasing, which raises the issue of their impact on the development of complications.AIM: to study the associations of overweight and obesity with vascular complications, cardiovascular risk factors and serum levels of vascular remodeling biomarkers in patients with T1D.MATERIALS AND METHODS: The study included 547 patients, including 309 with body mass index (BMI) 2, 155 with BMI 25–29.9 kg/m2, and 83 with BMI ≥30 kg/m2. Insulin sensitivity was assessed by the estimated glucose disposal rate. In the serum of 130 patients and 30 individuals with normal weight and normal glucose tolerance, concentrations of advanced glycation end products (AGEs), endothelin-1, endothelial NO synthase (NOS3), adrenomedullin (ADM), endothelial cell-specific molecule-1 (ESM1), cell adhesion molecules (ICAM-1 and VCAM-1), integrin-associated protein-1 (IAP-1), integrin receptor subunit (ITGB1), heme oxygenase-1 (HO-1), GAS6, decorin, and transforming growth factor β1 (TGF-β1) were determined by ELISA.RESULTS: Obesity in patients with T1D was independently associated with coronary artery disease, myocardial infarction, and chronic heart failure. Overweight was an independent predictor of chronic heart failure only. Patients with BMI ≥25 kg/m2, when compared with those with BMI 2, were older, had a reduced insulin sensitivity and increased levels of triglycerides, LDL-cholesterol, uric acid, and high-sensitivity C-reactive protein. Patients with T1D, as compared with controls, showed a significant increase in serum AGEs, endothelin-1, ICAM-1, VCAM-1, IAP-1, ESM1, HO-1, GAS6, and TGF-β1. Overweight patients, when compared with those with BMI 2, demonstrated higher levels of ICAM-1, IAP-1, ITGB1 and TGF-β1, while obese individuals had increased concentrations of AGEs, IAP-1 and HO-1.CONCLUSION: In patients with T1D, overweight and obesity are associated with vascular complications, their risk factors and biomarkers of vascular remodeling.


  • Analysis of Associations Between Advanced Glycation end-Products and Vascular Complications of type 2 Diabetes

    by Elena A. Koroleva, Vyacheslav V. Romanov

    The aim of the study: to determine the predictive value of advanced glycation end-products and their receptor in prognostic model for vascular complications of type 2 diabetes. Materials and Methods: 126 patients with type 2 diabetes (T2D), 55 males and 71 females were included. Testing for diabetes complications, comorbidities and laboratory parameters was realized. A duplex ultrasound of the carotid and lower extremities arteries was conducted for all patients to reveal or exclude the atherosclerosis. Serum concentrations of AGEs (advanced glycation end products) and RAGE (receptor for advanced glycation end products) were determined by enzyme-linked immunosorbent assay. Results: based on ultrasound data the examined patients were divided in three groups. First group without atherosclerosis (ATO, $\mathrm{n}=39)$ . Second group with atherosclerosis of carotid arteries $(\text{AT}1,\ \mathrm{n}=47)$ . Third group included the patients with atherosclerosis of carotid arteries and lower extremities $(\text{AT}2,\ \mathrm{n}=40)$ . The groups were similar by age and sex. The atherosclerosis was associated with T2D duration, lower BMI, diabetic nephropathy and chronic kidney disease. The differences in other clinical and metabolic parameters were not revealed. Serum concentrations of AGEs and RAGEs did not differ in the study groups. The correlation analysis revealed relationships between the AGEs and microalbuminuria $(\mathrm{r}=0.69,\ \mathrm{p} < 0.05)$ and urine albumin-creatinine ratio $(\mathrm{r}=0.67,\mathrm{p} < 0.05)$ . Conclusion: in T2D patients, serum levels of AGEs is associated with diabetic nephropathy. AGEs and RAGEs did not predict an atherosclerosis development and progression.

  • Open Access

    Serum level of proteins involved in apoptosis and autophagy in patients with type 2 diabetes and non-alcoholic fatty liver disease

    by Ya. A. Krasner, V. V. Romanov, O. N. Fazullina, M. F. Osipenko, V. V. Klimontov

    Aim of the study was to estimate the blood serum level of microtubule-associated protein 1 light chain 3 alpha (MAP1LC3alpha), beclin-1 (BECN-1), Bcl-2 (BCL-2), caspase-3 (CASP3) and autophagy related 5 (ATG-5) protein as potential markers of liver fibrosis in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD).Material and methods. A single center cross-sectional observational study was performed. Seventy four patients with T2D and NAFLD were included, 23 men and 51 women, aged 18 to 74 years. Transient elastography was used for the assessment of liver fibrosis. The severity of fibrosis was estimated using the Metavir sсore. In addition, indirect liver fibrosis indices APRI and FIB-4 were calculated. Serum concentration of MAP1LC3alpha, BECN-1, BCL-2, CASP and ATG-5 was measured by ELISA. We applied ROC analysis to assess the value of studied indicators in diagnosis of liver fibrosis.Results. Liver fibrosis stage F1 was verified in 16 subjects, stage F2 in 12, stage F3 in 7, and stage F4 in 19 individuals. Patients with advanced liver fibrosis (stage 3-4) when compared to those without fibrosis (stage 0–2) had higher content of MAP1LC3alpha (p = 0.01) and BECN-1 (p = 0.01). There were no significant differences in the level of BCL-2, CASP3 and ATG-5 between patients with different severity of fibrosis. In the ROC analysis, MAP1LC3alpha and BECN-1 showed significance for the diagnosis of severe liver fibrosis, which, however, did not exceed that of the APRI index.Conclusions. In patients with T2D and NAFLD, serum levels of MAP1LC3alpha and BECN-1 are associated with severe liver fibrosis.


  • Open Access

    Bleeding disorders associated with severity of respiratory failure in COVID-19 patients: a prospective observational study

    by Mikhail I. Neymark, A. P. Momot, M. G. Nikolaeva, А. N. Маmаеv, S. N. Proskurin, P. V. Logvinov, A. N. Karkavina, D. P. Epp, V. V. Romanov

    INTRODUCTION: Despite the progress in understanding the pathophysiology of coagulopathy in COVID-19, data about the association and phasing of pathological changes in various parts of the hemostatic system with the development of acute respiratory distress syndrome (ARDS) are insufficient. OBJECTIVE: To determine association between the severity of respiratory failure and pathological changes in the hemostatic system in COVID-19 patients. MATERIALS AND METHODS: A prospective observational study included 204 patients with a confirmed diagnosis of severe and extremely severe COVID-19. Two groups were identified according to disease outcome: fatal (n = 106) and survived (n = 98) groups. To assess dynamics of the clinical picture of the disease and to study the hemostatic profile, time points were determined: I point — the first day — admission to intensive care unit; II point — 3–5 days, III point — 7–10 days after ICU admission. The respiratory index was calculated to assess the severity of respiratory distress syndrome. Statistical data processing was carried out using the statistical software package MedCalc Version 20.110 (MedCalc Software Ltd, Belgium). RESULTS: A 2.15-fold decrease in the respiratory index was determined for fatal outcome in patients with severe and extremely severe COVID-19. The most important hemostatic parameters affecting the severity of respiratory failure are increased Willebrand factor concentration at I point of the study (21 % contribution and inverse correlation), increased plasminogen activator inhibitor type 1 (PAI-1) level on 3–5 days (35 % contribution and direct correlation), and activation of the coagulative component of hemostasis on 7–10 days (78 % contribution and direct correlation). CONCLUSIONS: The severity of respiratory failure in patients with a confirmed diagnosis of severe and extremely severe COVID-19 is gradually associated with endotheliopathy (1 day), inhibition of parietal fibrinolysis (3–5 days) and activation of the coagulative component of hemostasis by 7–10 days of ICU stay. АКТУАЛЬНОСТЬ: Несмотря на прогресс в понимании патофизиологии коагулопатии при COVID-19, сведений о связи и об этапности патологических сдвигов в различных звеньях системы гемостаза при развитии острого респираторного дистресс-синдрома (ОРДС) недостаточно. ЦЕЛЬ ИССЛЕДОВАНИЯ: Определить взаимосвязь тяжести дыхательной недостаточности с патологическими сдвигами в системе гемостаза у больных COVID-19. МАТЕРИАЛЫ И МЕТОДЫ: В проспективное наблюдательное исследование включено 204 больных с верифицированным диагнозом COVID-19 тяжелого и крайне тяжелого течения заболевания. В зависимости от исхода заболевания выделено две группы: группа с летальным исходом (n = 106) и группа выживших больных (n = 98). Для динамической оценки клинической картины заболевания и исследования показателей системы гемостаза определены временные точки: точка I — 1-е сутки, поступление в отделение реанимации и интенсивной терапии (ОРИТ); точка II — 3–5-е сутки; точка III — 7–10-е сутки с момента поступления в ОРИТ. Для оценки тяжести респираторного дистресс-синдрома рассчитывался респираторный индекс. Статистическую обработку данных проводили с использованием пакета статистического программного обеспечения MedCalc Version 20.110 (MedCalc Software Ltd, Бельгия). РЕЗУЛЬТАТЫ: При летальном исходе заболевания COVID-19 тяжелого и крайне тяжелого течения у пациентов определено снижение показателя респираторного индекса в 2,15 раза. Наиболее важные параметры системы гемостаза, влияющие на степень тяжести дыхательной недостаточности: рост концентрации фактора Виллебранда (WF) на точке I исследования (21 % вклада и обратная корреляция), увеличение уровня ингибитора активатора плазминогена 1-го типа (PAI-1) на 3–5-е сутки (35 % вклада и прямая корреляция) и активация коагуляционного звена гемостаза на 7–10-е сутки (78 % вклада и прямая корреляция). ВЫВОДЫ: Степень тяжести дыхательной недостаточности у пациентов с подтвержденным диагнозом COVID-19 тяжелого и крайне тяжелого течения поэтапно связана с эндотелиопатией (1-е сутки), угнетением пристеночного фибринолиза (3–5-е сутки) и активацией коагуляционного звена гемостаза к 7–10-м суткам пребывания в ОРИТ.


  • Open Access

    Clinical and laboratory characteristics of the patterns of chronic kidney disease in patients with type 2 diabetes

    by Vadim V. Klimontov, Anton I. Korbut, Olga N. Fazullina, Ilya V. Vinogradov, Vyacheslav V. Romanov

    BACKGROUND: A growing body of evidence demonstrates increasing prevalence of normoalbuminuric chronic kidney disease (NA-CKD) in subjects with type 2 diabetes (T2D), while proportion of albuminuric pattern is decreasing. AIMS: To determine the clinical and laboratory parameters associated with different patterns of CKD in patients with T2D. METHODS: This observational, single-center, cross-sectional study included 360 patients with T2D duration 10 years. Patients with urinary albumin/creatinine ratio (UACR) 3 mg/mmol and estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2 were classified as no-CKD group (n=89). Patients with UACR 3 mg/mmol and eGFR 60 ml/min/1.73 m2 formed NA-CKD group (n=111). Individuals with eGFR 60 ml/min/1.73 m2 and UACR mg/mmol 3 were recorded as albuminuric with preserved renal function (A-CKD, n=87). Patients with eGFR 60 ml/min/1.73 m2 and UACR mg/mmol 3 mg/mmol were considered as albuminuric CKD group (A-CKD+, n=73). Urinary nephrin and podocin, the podocyte injury markers, and whey acidic protein four-disulfide core domain protein 2 (WFDC-2), a marker of tubulointerstitial involvement, was assessed by ELISA and compared to control (20 non-diabetic subjects). RESULTS: Age 65 years (p=0.0001), duration of T2D 15 years (p=0.0009), female sex (p=0.04), and therapy with diuretics (p=0.0005) were found as risk factors for NA-CKD. The risk factors for A-CKD were male sex (p=0.01), smoking (p=0.01), waist-to-hip ratio 1 (p=0.01) and HbA1c levels 8% (p=0.005). The duration of T2D 15 years (p=0.01) and the use of dihydropyridine calcium channel blockers (p=0.01) were associated with A-CKD+. In T2D groups, the urinary excretion of nephrin and podocin was increased (all p0.001), more markedly in albuminuric individuals (p0.01 vs. NA-CKD). WFDC-2 excretion was increased in men from all diabetic groups (p0.05) and in women with decreased eGFR only (p0.05 vs. the control and NA-CKD). CONCLUSIONS: The CKD patterns in T2D are heterogeneous according to their clinical and laboratory characteristics. The changes in the excretion of nephrin and podocin indicate the association of albuminuric patterns with podocyte injury. A decrease in eGFR in women with T2D is associated with an increase in urinary excretion of WFDC-2, tubulointerstitial fibrosis marker.


  • Assessment of hemostasis in physiological pregnancy. Algorithms of examination in high risk groups. Guidelines (PROJECT), 2nd edition

    by Андрей Павлович Момот, М.г. Николаева, Г.в. Сердюк, А.н. Мамаев, В.в. Романов, И.ю. Кудинова, Д.е. Белозеров, Д.а. Трухина, Н.в. Максимова, Ж.и. Вахлова

    Настоящие методические рекомендации представляют собой изложение алгоритмов исследования системы гемостаза у беременных при физиологическом течении беременности и в группах риска по развитию гестационных и тромбоэмболических осложнений и акушерских кровотечений. These guidelines are the summary of algorithms for the study of hemostasis in pregnant women during the physiological pregnancy and in risk groups for the development of gestational and thromboembolic complications and obstetric hemorrhages.


  • Open Access

    Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes

    by Anton I Korbut, Vadim V Klimontov, Ilya V Vinogradov, Vyacheslav V Romanov

    Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes


  • Open Access

    PULMONARY TUBERCULOSIS WITH MULTIPLE DRAG-RESISTANT M. TUBERCULOSIS IN PATIENTS WITH DIABETES MELLITUS

    by O. G Komissarova, Rizvan Yu.O. Abdullaev, S. V Aleshina, V. V Romanov

    The aim of the study was to study the clinical manifestations and effectiveness of treatment of pulmonary tuberculosis with multidrug-resistant (MDR M. tuberculosis (MTB) in patients with different types of diabetes mellitus (DM). 66 patients with pulmonary tuberculosis combined with type 1 diabetes mellitus and 48 patients with pulmonary tuberculosis combined with type 2 diabetes were examined. It was found that in patients with type 1 DM, MDR tuberculosis was more often observed in men under 40 years of age, in the form of infiltrative pulmonary tuberculosis with the presence of destruction in lung tissue up to 2 cm in diameter with positive sputum and acute intoxication. In patients with type 2 DM, MDR tuberculosis was more often observed in men over the age of 40 in the form of fibrous-cavernous tuberculosis with the presence of destruction in lung tissue larger than 2 cm in diameter, with positive sputum and moderately severe intoxication. The effectiveness of treatment for negativation sputum in the compared groups did not differ significantly and amounted to 71,2% and 64,7%, respectively. However, to close the caverns in the lung, the treatment was more effective in patients with type 1 diabetes, which is probably due to the peculiarities of the tuberculosis process in this category of patients.


  • Open Access

    Urinary excretion of type IV collagen as an early marker of renal fibrosis in patients with diabetes mellitus

    by Irina Arkad'EVna Bondar', Vadim Valer'EVich Klimontov, Ekaterina Mikhailovna Parfent'EVa, Vyacheslav Vital'EVich Romanov, Alexander Petrovich Nadeev

    Aim. To determine the diagnostic value of urinary excretion of type IV collagen in patients with type 1 diabetes with different stages of nephropathy.Methods. Urinary type IV collagen was determined in 60 patients with type 1 diabetes (23 with normal albuminuria, 28 with microalbuminuriaand 9 with macroalbuminuria) by an enzyme immunoassay. 10 healthy individuals were acted as the control group. Renal biopsy was performedin 22 patients. Deposits of type IV collagen were revealed by 11 individuals by immunohistochemistry. Results. The urinary excretion of type IV collagen increased with severety of diabetic nephropathy, correlating with the urinary albumin/creatinineratio, serum creatinine and parameters of daytime and nighttime systolic and diastolic blood pressure. Patients with excessive accumulation of typeIV collagen in the glomeruli had significantly higher level of type IV collagen in the urine. Conclusion. The determination of urinary type IV collagen can be used for early detection of renal fibrosis in patients with type 1 diabetes.